PomDoctor Ltd. (POM) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$1.50

From 52W high−98.53%

Volume226745.00

Market cap$4.48M

P/E (TTM)—

P/S (TTM)0.1x

Div yield—

Key dataNov 4, 2026

Open

$1.50

From 52W high

−98.53%

Volume

226745.00

Market cap

$4.48M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.3x

P/E (TTM)

—

RSI (14)

47.1

MomentumView details →

1D Return

+8.78%

YTD Return

−70.06%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.3x

EV/Sales

0.3x

P/S (TTM)

0.1x

P/B (TTM)

−0.4x

ProfitabilityView details →

Gross Margin

11.68%

Net Margin

−83.71%

EBITDA Margin

−74.05%

ROE (TTM)

416.40%

ROA (TTM)

−2573.37%

Asset Turnover

7.90x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+17.71%

EPS CAGR 3Y

+3.35%

EBITDA YoY

—

MomentumView details →

1D Return

+8.78%

YTD Return

−70.06%

1Y Return

−98.54%

RSI (14)

47.1

vs 50D SMA

−3.53%

vs 200D SMA

−47.42%

Capital & dividendView details →

Debt/Equity

−0.96x

Current Ratio

0.35x

Quick Ratio

0.32x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

345.02M

Net Income (TTM)

−288.80M

Op. CF (TTM)

−126.98M

Latest newsMore news →

Pomdoctor outlined its strategic evolution toward a four-tier revenue structure spanning B2C healthcare services, AI-enabled chronic disease management, B2B enterprise and hospital services, and pharmaceutical RWS/RWD services.7h ago

Pomdoctor Limited provided an update on the continued development and commercialization of its AI-enabled chronic disease management ecosystem, including optimization of its proprietary AI chronic disease management system, expanded real-world data applications, and integrated in-hospital and out-of-hospital chronic disease management pilots.35d ago

Similar companies

Cellyan Biotechnology Co., LtdHKPD Bio Green Med Solution, Inc.BGMS Eocene Ltd.EOCN Plus Therapeutics, Inc.CNSY Bio Green Med Solution, Inc.BGMSP Hoth Therapeutics, Inc.RKTO Find similar companies →

Latest newsMore news →

Pomdoctor outlined its strategic evolution toward a four-tier revenue structure spanning B2C healthcare services, AI-enabled chronic disease management, B2B enterprise and hospital services, and pharmaceutical RWS/RWD services.7h ago Pomdoctor Limited provided an update on the continued development and commercialization of its AI-enabled chronic disease management ecosystem, including optimization of its proprietary AI chronic disease management system, expanded real-world data applications, and integrated in-hospital and out-of-hospital chronic disease management pilots.35d ago